NMRA Neumora Therapeutics, Inc.
Company Analysis
Latest News
🟢 NMRA is trading 5.9% up today with no clear fresh catalyst
NMRA is trading about 5.9% up now at $1.72, bouncing from recent weakness after June’s Phase 3 KOASTAL trial failure and workforce reduction, which triggered a...
🔴 Neumora Therapeutics, Inc. is trading 5.88% down
NMRA is trading at $1.60, down 5.88%.
🟢 NMRA is trading 5% up today as it extends its rebound from a Phase 3 trial failure selloff
NMRA is trading 5% up today at $1.73 as the stock continues to rebound from a recent selloff triggered by a Phase 3 depression trial failure. • Today's price...
🟢 NMRA is trading 6.7% up today as it extends rebound from trial-failure selloff
NMRA is trading at $1.75 (6.7% up) in pre-market, extending a recovery following the sharp selloff triggered by its Phase 3 depression trial failure. • Recent...
🟢 NMRA is trading 5.3% up today on technical rebound after trial-failure selloff
NMRA is trading 5.3% up at $1.59 on a technical rebound following a sharp selloff earlier this month. • The move appears driven by bargain hunting and...
🟢 NMRA is trading 6% up today on technical repricing after recent trial failure selloff
NMRA is trading 6% up today at $1.60 in pre-market, seeing a modest bounce following a significant collapse earlier this month. • The stock's recent decline...
🔴 NMRA makes sharp 10.9% drop
NMRA is trading at $1.44, down 10.9% versus the comparison close of $1.61 during regular trading. This is a price-movement alert; no separate company-specific...
🔴 NMRA is trading 8.2% down today as selling persists after drug failures and restructuring
NMRA is trading 8.2% down at $1.48 as investors continue to sell following the company’s late-stage depression drug failures and restructuring moves. • The...
Neumora's Depression Drug Struck Out Three Times — Can a Gutted Biotech Pivot Its Way Back From the Brink?
Shares of Neumora Therapeutics sank another 10.1% to $1.45 in pre-market trading Tuesday, extending a brutal selloff that has erased roughly 95% of the stock's...
🔴 NMRA is trading 10.1% down today after Phase 3 trial failures and ongoing legal probes
NMRA is trading at $1.45 (10.1% down) in pre-market, extending recent volatility after its lead depression drug navacaprant failed multiple Phase 3 KOASTAL...
🔴 Neumora Therapeutics, Inc. is trading 9.9% down today, extending recent volatility after last week’s extreme swings
Neumora Therapeutics, Inc. is trading 9.9% down at $1.36 in pre-market, extending its recent volatility after last week’s extreme swings. • The decline...
🔴 Neumora Therapeutics, Inc. is trading 5.2% down today following Phase 3 trial failures and workforce reductions
Neumora Therapeutics, Inc. is trading 5.2% down at $1.45, extending a sharp sell-off triggered by the failure of its lead depression drug candidate. • The...